LA-Azepane
 | |
 | |
| Clinical data | |
|---|---|
| Other names | LSD-Azepane; Lysergic acid azepane; Lysergic acid hexamethylene imide; N-(Azepan-1-yl)lysergamide |
| ATC code |
|
| Identifiers | |
| |
| Chemical and physical data | |
| Formula | C22H27N3O |
| Molar mass | 349.478 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
LA-Azepane, or LSD-Azepane, also known as lysergic acid azepane or as lysergic acid hexamethylene imide, is a chemical compound of the lysergamide family related to lysergic acid diethylamide (LSD).[1] It is an derivative of LSD in which the N,N-diethylamide moiety has been cyclized to form an azepane ring.[1] The compound is very little studied and described itself, but is closely related to other amide-cyclized LSD analogues including LA-Pip, LSM-775 (LA-Morph), LPD-824 (LA-Pyr), LPN, LSZ (LA-Azetidide), and LA-Aziridine, among others.[2][3] The chemical synthesis of the compound has been described.[1] LA-Azepane was first described in the literature in a patent by Richard P. Pioch at Eli Lilly and Company in 1961.[1] The patent had been filed 5 years previously in 1956.[1]
See also
[edit]References
[edit]- 1 2 3 4 5 US 2997470, Pioch RP, "Lysergic acid amides", issued 22 August 1961, assigned to Eli Lilly and Company EXAMPLE 38 Preparation of d-lysergic acid hexamethylene imide: [...]
- ↑ Nichols DE (2018). Chemistry and Structure-Activity Relationships of Psychedelics. Current Topics in Behavioral Neurosciences. Vol. 36. pp. 1–43. doi:10.1007/7854_2017_475. ISBN 978-3-662-55878-2. PMID 28401524.
Table 1 5-HT2A 5-HT2C, and 5-HT1A receptor affinity and functional effects for selected lysergamides [...]
- ↑ Nichols DE (2012). "Structure–activity relationships of serotonin 5-HT2A agonists". Wiley Interdisciplinary Reviews: Membrane Transport and Signaling. 1 (5): 559–579. doi:10.1002/wmts.42. ISSN 2190-460X.
External links
[edit] | This hallucinogen-related article is a stub. You can help Wikipedia by adding missing information. |